# Peter Goodwin
Topp podcast avsnitt
Uppdaterad:
Dr peter goodwin is chairman of the department of Journalism and Mass Communication at the University of Westminster.
== Work ==
He is the author of Television under the Tories: Broadcasting Policy 1979 - 1997.
His areas of expertise are political economy of the media; media policy; media and politics; the television industry; and the social and economic impact of new media technologies.
The Legacy That Matters: Fatherhood, Money, Marriage, and Stewardship with Peter Goodwin
Todd Wagner sits down with Peter Goodwin, founder of Groove and The Quarry Project, for a conversation about fatherhood, marriage, money, leadership, and the legacy we build at home.
Peter shares how God has shaped his view of success, challenged him to steward wealth with purpose, and called men …
Robert C. Stein, PhD FRCP; ASCO 2026: Gene Test Finds Most Patients with High Risk ER-positive, HER2-negative Early Breast Cancer Do Not Benefit from Chemotherapy
The idea that all women with hormone dependent early breast cancers that test negative for the HER2 molecule and have high risk clinical factors should be receive chemotherapy in addition to endocrine therapy is now being strongly questioned. A new study using a gene expression test to predict rec…
John Mascarenhas MD; ASCO 2026: New Janus Kinase Inhibitor Improves Myelofibrosis Outcomes When Added to Ruxolitinib Initial Therapy
CHICAGO, USA—Outcomes were improved for patients with myelofibrosis in the phase 3 SENTRY trial who were randomized to have the new Janus kinase inhibitor selinexor added to their ruxolitinib initial therapy.Findings were reported at the 2026 Annual Meeting of the American Society of Clinical Oncol…
David R Spigel MD; ASCO 2026: EGFR Exon-20 Insertion Directed Initial Therapy Cuts Disease Progression in Patients with Advanced Non-Small Cell Lung Cancer
CHICAGO, USA—For patients with advanced non-small cell lung cancer harboring the rare exon-20 gene insertion,first-line treatment with the targeted drug sunvozertinib monotherapy brought statistically significant anti-tumor efficacy when compared with chemotherapy in the phase three WU-KONG28 study…
Entrepreneurial Leadership – Peter Goodwin
Peter Goodwin shares how he turned a brilliant idea into a profitable business by taking calculated risks, hiring the right people and building a great company culture.
Jiujie Cui MD PhD, CSCO 2026: Early Findings Show KRAS-G12D Inhibitor More than Doubles Median Overall Survival in Patients with Advanced Pancreatic Cancer
JINAN, China—A highly selective drug that inhibits the predominant oncogenic driver (the KRAS-G12D mutation) in advanced pancreatic ductal adenocarcinoma, and minimizes side effects, has shown big promise for keeping patients alive and progression-free. This was in early trial results reported at t…
Feng Wang PhD MD; CSCO 2026: Progress and Prospects of New Drug Research for Colorectal Cancer: The View from China
JINAN, China—The 2026 Annual Meeting of the Chinese Society of Clinical Oncology, with more than 40 000 cancer clinicians attending, heard evidence from clinical trial findings and new science bringing great hope for the treatment of colorectal cancer.
The era of targeted precision medicine for co…
Fang Wu MD PhD; CSCO 2026: Could Emotional Distress Medicines Prolong Survival in Patients with Small Cell Lung Cancer?
JINAN, China—Provocative evidence is emerging that emotional distress can adversely affect outcomes among patients with lung cancer. Data from a study of the role of hormones in affecting lung cancer outcomes were reported at the 2026 Annual Meeting of the Chinese Society of Clinical Oncology in an…
Thomas E. Stinchcombe MD; CSCO 2026: The Journal of Clinical Oncology’s Mission and Vision Going Forwards: New Editor's Global Perspective
JINAN, China—January 2027 sees the appointment of the new Editor-in-Chief of the Journal of Clinical Oncology who tells us (during his visit to China) he is committed to continue the policy of global co-operation in clinical cancer research publishing.
He is: Thomas Eldridge Stinchcombe MD, FASCO,…
David R Spigel MD; ASCO 2026: Bispecific PD-1/VEGF Antibody Ivonescimab Extends Life in Patients with Untreated Advanced Non–Small Cell Lung Cancer: Phase 3 HARMONi-6 trial
CHICAGO, USA—The bispecific antibody ivonescimab (that targets the PD-1 and VEGF molecules) has extended overall survival in patients with untreated advanced squamous non-small cell lung cancer in the latest data from the HARMONi-6 trial reported at the 2026 Annual Meeting of the American Society o…
PODCAST SÖKMOTOR
Du kan använda vår webbplats för att söka efter3,825,883podcaster och195,955,146avsnitt efter personer, platser eller ämnen.
If I have seen further than others, it is by listening to podcasts and standing upon the shoulders of
giants.
‐ Isaac "Llamacorn" Newton
REDIGERA
Tack för att du hjälper till att hålla databasen över podcaster uppdaterad.
